Bayer Reports Phase 3 PET Data in Cardiac Amyloidosis
Berlin, Germany, August 30, 2026 Bayer announced detailed results from the Phase 3 REVEAL study evaluating investigational PET radiotracer...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Berlin, Germany, August 30, 2026 Bayer announced detailed results from the Phase 3 REVEAL study evaluating investigational PET radiotracer...
Durham, North Carolina, August 29, 2026 AskBio Inc. presented baseline characteristics from its Phase 2 GenePHIT clinical trial evaluating...
Cambridge, Massachusetts, August 27, 2026 Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved supplemental...
NEW YORK, NY and MAINZ, Germany – August 27, 2026 Pfizer Inc. and BioNTech SE announced that the U.S....
NEW YORK and MAINZ, Germany, July 29, 2026 Pfizer Inc. and BioNTech SE announced that the European Commission (EC)...
WASHINGTON, May 13, 2026 The Sabin Vaccine Institute honored renowned vaccine researchers Professor Uğur Şahin and Professor Özlem Türeci...
NEW YORK & MAINZ, Germany – September 8, 2025 – Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)...
GAITHERSBURG, Md., August 27, 2025 – The U.S. Food and Drug Administration (FDA) has granted approval for Novavax’s Nuvaxovid™...
